학술논문
Effect of CD34+Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
Document Type
Article
Author
Pedraza, Alexandra; Salas, María Queralt; Rodríguez-Lobato, Luis Gerardo; Charry, Paola; Suárez-Lledo, María; Martínez-Cibrian, Nuria; Doménech, Ariadna; Solano, Maria Teresa; Arcarons, Jordi; de Llobet, Noemí; Rosiñol, Laura; Gutiérrez-García, Gonzalo; Avilés, Francesc Fernández; Urbano-Ispízua, Álvaro; Rovira, Montserrat; Martínez, Carmen
Source
Transplantation and Cellular Therapy; 20230101, Issue: Preprints
Subject
Language
ISSN
26666375; 26666367
Abstract
•CD34+cell dose did not impact survival outcomes after matched sibling donor, matched unrelated donor, and mismatched unrelated donor allogeneic hematopoietic stem cell transplantation (alloHSCT) with post-transplantation cyclophosphamide (PTCy).•Infusion of <5 × 106/kg CD34+cells reduces overall survival in haploidentical alloHSCT recipients.•Earliest engraftment occurs at a CD34+cell dose of 5 to 8 × 106/kg, independent of donor type.•A CD34+cell dose of 5 to 8 × 106/kg is recommended in PTCy alloHSCT, regardless of donor type.